$1.79
-0.14-7.01%
最終更新: Oct 19, 4:25 AM
$1.79
-0.14-7.01%
Benzinga
Benzinga
Benzinga
月曜日, 10 19
Benzinga
© 2026 Benzinga | All Rights Reserved
Fate Therapeutics (FATE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.26 | $-0.28 | $-0.27 | $-0.28 |
| Actual | $-0.25 | $-0.26 | $-0.27 | $-0.27 |
| Surprise | +3.85% | +7.14% | 0.00% | +3.57% |
| Revenue | ||||
| Estimate | $1.2M | $1.6M | $1.3M | $1.3M |
| Actual | $2.1M | $1.3M | $1.4M | $1.7M |
| Surprise | +70.8% | -18.1% | +3.80% | +29.1% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.26 | $-0.28 | $-0.25 | $-0.26 |
| Revenue | ||||
| Consensus | $1.3M | $1.3M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $-0.25 | $-0.26 | 3.85 % |
| Q1 | May 13, 2026 | $-0.26 | $-0.28 | 7.14 % |
| Q4 | Feb 26, 2026 | $-0.27 | $-0.27 | 0.00 % |
| Q3 | Nov 13, 2025 | $-0.27 | $-0.28 | 3.57 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 13, 2026 | $2.08M | $1.22M | 70.8 % |
| Q1 | May 13, 2026 | $1.30M | $1.59M | -18.1 % |
| Q4 | Feb 26, 2026 | $1.37M | $1.32M | 3.80 % |
| Q3 | Nov 13, 2025 | $1.74M | $1.35M | 29.1 % |